Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arrowhead Pharmaceuticals Inc ARWR

Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform... see more

Recent & Breaking News (NDAQ:ARWR)

Arrowhead to Present at Jefferies 2015 Hepatitis B Summit

Business Wire August 5, 2015

Arrowhead Reports Fiscal 2015 Third Quarter Financial Results

Business Wire August 4, 2015

Biotech Sector Review

Accesswire August 4, 2015

Biotech Sector Review

Accesswire August 4, 2015

Arrowhead to Report Fiscal 2015 Third Quarter Financial Results

Business Wire July 28, 2015

Arrowhead Receives Regulatory Clearance for ARC-AAT Phase 1 in the United Kingdom and New Zealand

Business Wire July 8, 2015

Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency

Business Wire July 2, 2015

Arrowhead Receives Regulatory Clearance to Begin Additional Phase 2b Studies of Hepatitis B Candidate ARC-520

Business Wire June 17, 2015

Arrowhead Receives Orphan Drug Designation for ARC-AAT

Business Wire June 10, 2015

Arrowhead to Present at Jefferies 2015 Healthcare Conference

Business Wire May 27, 2015

Arrowhead Reports Fiscal 2015 Second Quarter Financial Results

Business Wire May 11, 2015

Arrowhead Presents Data on Potential RNAi Candidate Targeting Factor 12 Mediated Angioedemic and Thromboembolic Diseases

Business Wire May 6, 2015

Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT

Business Wire May 5, 2015

Arrowhead to Report Fiscal 2015 Second Quarter Financial Results

Business Wire May 4, 2015

Arrowhead Publishes Data on Advances in Subcutaneous siRNA Delivery

Business Wire April 30, 2015

Arrowhead to Present at Upcoming Conferences

Business Wire April 28, 2015

Arrowhead Cleared to Proceed with Multiple Dose Phase 2b Study of ARC-520

Business Wire April 13, 2015

Arrowhead Acquires Novartis' RNAi Research and Development Portfolio

Business Wire March 5, 2015

Arrowhead to Present at 2015 Barclays Global Healthcare Conference

Business Wire March 4, 2015

Arrowhead Begins Phase 1 Trial of ARC-AAT for Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency

Business Wire February 23, 2015